CEL-SCI CORPORATION Interest Expense
CEL-SCI CORPORATION (CVM) reported Interest Expense of $111.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement
us-gaap:InterestExpense · last filed 2026-08-14
- CEL-SCI CORPORATION interest expense for the quarter ending 2026-06-30 was $111.00K, a 35.47% decline year-over-year.
- CEL-SCI CORPORATION interest expense for the quarter ending 2026-03-31 was $117.00K, a 34.27% decline year-over-year.
- CEL-SCI CORPORATION interest expense for the quarter ending 2025-12-31 was $88.00K, a 48.24% decline year-over-year.
- CEL-SCI CORPORATION interest expense for the quarter ending 2025-09-30 was $129.00K.
- CEL-SCI CORPORATION interest expense for fiscal 2025 was $649.00K, a 13.00% decline from fiscal 2024.
- CEL-SCI CORPORATION interest expense for fiscal 2024 was $746.00K, a 10.45% increase from fiscal 2023.
- CEL-SCI CORPORATION interest expense for fiscal 2023 was $675.42K, a 37.52% decline from fiscal 2022.
- CEL-SCI CORPORATION interest expense for fiscal 2022 was $1.08M.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $111.00K 10-Q · filed 2026-08-14 | $228.00K derived: sum of 2 quarters · filed 2026-08-14 | $316.00K 10-Q · filed 2026-08-14 | $445.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $117.00K 10-Q · filed 2026-05-15 | $205.00K 10-Q · filed 2026-05-15 | $334.00K derived: sum of 3 quarters · filed 2026-05-15 | $506.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $88.00K 10-Q · filed 2026-02-17 | $217.00K derived: sum of 2 quarters · filed 2026-02-17 | $389.00K derived: sum of 3 quarters · filed 2026-08-14 | $567.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-09-30 | $129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-29 | $301.00K derived: sum of 2 quarters · filed 2026-08-14 | $479.00K derived: sum of 3 quarters · filed 2026-08-14 | $649.00K 10-K · filed 2025-12-29 | |||
| 2025-06-30 | $172.00K 10-Q · filed 2026-08-14 | $350.00K derived: sum of 2 quarters · filed 2026-08-14 | $520.00K 10-Q · filed 2026-08-14 | ||||
| 2025-03-31 | $178.00K 10-Q · filed 2026-05-15 | $348.00K 10-Q · filed 2026-05-15 | |||||
| 2024-12-31 | $170.00K 10-Q · filed 2026-02-17 | ||||||
| 2024-09-30 | $746.00K 10-K · filed 2025-12-29 | $745.67K 10-K · filed 2025-01-13 | |||||
| 2023-09-30 | $675.42K 10-K · filed 2025-01-13 | ||||||
| 2022-09-30 | $1.08M 10-K · filed 2023-12-21 | ||||||
| 2020-09-30 | $1.19M derived: 10-K 12 month − 10-Q/A 9 month · filed 2020-12-29 | $1.20M derived: sum of 2 quarters · filed 2020-12-31 | $1.20M 10-K · filed 2020-12-29 | ||||
| 2020-06-30 | $6.00K 10-Q/A · filed 2020-12-31 | $6.00K 10-Q/A · filed 2020-12-31 | |||||
| 2016-12-31 | $469.15K 10-Q/A · filed 2017-12-11 | ||||||
| 2015-12-31 | $483.69K 10-Q/A · filed 2017-12-11 | $488.80K derived: sum of 2 quarters · filed 2017-12-11 | $530.39K derived: sum of 3 quarters · filed 2017-12-11 | $572.02K derived: sum of 4 quarters · filed 2017-12-11 | |||
| 2015-09-30 | $5.10K derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | $46.70K derived: sum of 2 quarters · filed 2015-12-11 | $88.33K derived: sum of 3 quarters · filed 2015-12-11 | $129.99K 10-K · filed 2015-12-11 | |||
| 2015-06-30 | $41.59K 10-Q · filed 2015-08-07 | $83.22K derived: sum of 2 quarters · filed 2015-08-07 | $124.88K 10-Q · filed 2015-08-07 | $166.57K derived: sum of 4 quarters · filed 2015-12-11 | |||
| 2015-03-31 | $41.63K 10-Q · filed 2015-05-08 | $83.29K 10-Q · filed 2015-05-08 | $124.98K derived: sum of 3 quarters · filed 2015-12-11 | $166.70K derived: sum of 4 quarters · filed 2015-12-11 | |||
| 2014-12-31 | $41.66K 10-Q · filed 2015-02-06 | $83.35K derived: sum of 2 quarters · filed 2015-12-11 | $125.07K derived: sum of 3 quarters · filed 2015-12-11 | $162.75K derived: sum of 4 quarters · filed 2015-12-11 | |||
| 2014-09-30 | $41.69K derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | $83.41K derived: sum of 2 quarters · filed 2015-12-11 | $121.09K derived: sum of 3 quarters · filed 2015-12-11 | $163.77K 10-K · filed 2015-12-11 | |||
| 2014-06-30 | $41.72K 10-Q · filed 2015-08-07 | $79.40K derived: sum of 2 quarters · filed 2015-08-07 | $122.08K 10-Q · filed 2015-08-07 | $164.70K derived: sum of 4 quarters · filed 2015-12-11 | |||
| 2014-03-31 | $37.68K 10-Q · filed 2015-05-08 | $80.36K 10-Q · filed 2015-05-08 | $122.98K derived: sum of 3 quarters · filed 2015-12-11 | $165.74K derived: sum of 4 quarters · filed 2015-12-11 | |||
| 2013-12-31 | $42.68K 10-Q · filed 2015-02-06 | $85.30K derived: sum of 2 quarters · filed 2015-12-11 | $128.06K derived: sum of 3 quarters · filed 2015-12-11 | $170.83K derived: sum of 4 quarters · filed 2015-12-11 | |||
| 2013-09-30 | $42.62K derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | $85.38K derived: sum of 2 quarters · filed 2015-12-11 | $128.15K derived: sum of 3 quarters · filed 2015-12-11 | $170.42K 10-K · filed 2015-12-11 | |||
| 2013-06-30 | $42.76K 10-Q · filed 2014-08-08 | $42.69K 10-Q · filed 2013-08-09 | $85.53K derived: sum of 2 quarters · filed 2014-08-08 | $127.80K 10-Q · filed 2014-08-08 | $168.33K derived: sum of 4 quarters · filed 2014-12-23 | ||
| 2013-03-31 | $42.76K 10-Q · filed 2014-05-12 | $85.11K 10-Q · filed 2014-05-12 | $125.57K derived: sum of 3 quarters · filed 2014-12-23 | $166.97K derived: sum of 4 quarters · filed 2014-12-23 | |||
| 2012-12-31 | $41.40K 10-Q · filed 2014-02-10 | $82.80K derived: sum of 2 quarters · filed 2014-12-23 | $124.21K derived: sum of 3 quarters · filed 2014-12-23 | $180.15K derived: sum of 4 quarters · filed 2014-12-23 | |||
| 2012-09-30 | $41.40K derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-23 | $82.80K derived: sum of 2 quarters · filed 2014-12-23 | $138.75K derived: sum of 3 quarters · filed 2014-12-23 | $262.21K 10-K · filed 2014-12-23 | |||
| 2012-06-30 | $41.40K 10-Q · filed 2013-08-09 | $97.35K derived: sum of 2 quarters · filed 2013-08-09 | $220.81K 10-Q · filed 2013-08-09 | $394.75K derived: sum of 4 quarters · filed 2013-12-27 | |||
| 2012-03-31 | $55.95K 10-Q · filed 2013-05-10 | $179.41K 10-Q · filed 2013-05-10 | $353.35K derived: sum of 3 quarters · filed 2013-12-27 | $419.59K derived: sum of 4 quarters · filed 2013-12-27 | |||
| 2011-12-31 | $123.46K 10-Q · filed 2013-02-08 | $297.40K derived: sum of 2 quarters · filed 2013-12-27 | $363.64K derived: sum of 3 quarters · filed 2013-12-27 | $405.04K derived: sum of 4 quarters · filed 2013-12-27 | |||
| 2011-09-30 | $173.94K derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-27 | $240.18K derived: sum of 2 quarters · filed 2013-12-27 | $281.58K derived: sum of 3 quarters · filed 2013-12-27 | $322.98K 10-K · filed 2013-12-27 | -$322.98K 10-K · filed 2011-12-23 | ||
| 2011-06-30 | $66.24K 10-Q · filed 2012-08-09 | -$66.24K 10-Q · filed 2011-08-09 | $107.64K derived: sum of 2 quarters · filed 2012-08-09 | $149.04K 10-Q · filed 2012-08-09 | -$149.04K 10-Q · filed 2011-08-09 | $432.29K derived: sum of 4 quarters · filed 2012-12-14 | |
| 2011-03-31 | $41.40K 10-Q · filed 2012-05-10 | $82.80K 10-Q · filed 2012-05-10 | $366.05K derived: sum of 3 quarters · filed 2012-12-14 | $324.65K derived: sum of 4 quarters · filed 2012-12-14 | |||
| 2010-12-31 | $41.40K 10-Q · filed 2012-02-09 | $324.65K derived: sum of 2 quarters · filed 2012-12-14 | $283.25K derived: sum of 3 quarters · filed 2012-12-14 | ||||
| 2010-09-30 | $283.25K derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-14 | $241.85K derived: sum of 2 quarters · filed 2012-12-14 | $162.33K 10-K · filed 2012-12-14 | -$162.33K 10-K · filed 2011-12-23 | |||
| 2010-06-30 | -$41.40K 10-Q · filed 2011-08-09 | -$120.92K 10-Q · filed 2011-08-09 | |||||
| 2009-09-30 | -$397.92K 10-K · filed 2011-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |